ReviewJournal of clinical hypertension (Greenwich, Conn.)2014
Endocan: a new molecule playing a role in the development of hypertension and chronic kidney disease?
Review in Journal of clinical hypertension (Greenwich, Conn.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 36 citations in OpenAlex.
- Blood biomarkers and atrial remodeling in patients at risk of atrial fibrillation.Frontiers in molecular medicine · 2026Article
- Serum Endocan as a Predictor of Survival and Cardiovascular Events in Patients Without Diabetic Kidney Disease on Chronic Haemodialysis: A Prospective, Observational Study.Medicina (Kaunas, Lithuania) · 2025Observational
- Oncogenic HPV-induced high expression of ESM1 predicts poor prognosis and regulates aerobic glycolysis in cervical cancer.iScience · 2024Article
- Potential Role of Novel Cardiovascular Biomarkers in Pediatric Patients with Chronic Kidney Disease.Mini reviews in medicinal chemistry · 2024Review
- Endocan Knockdown Down-Regulates the Expression of Angiogenesis-Associated Genes in Il-1ß Activated Chondrocytes.Biomolecules · 2023Article
- Prognostic and Diagnostic Value of Endocan in Kidney Diseases.International journal of nephrology · 2022Review
- Decreased expression of endothelial cell specific molecule-1 in lung tissue in emphysematous mice and stable COPD patients.Iranian journal of basic medical sciences · 2020Article
- The Role of Endocan in Selected Kidney Diseases.International journal of molecular sciences · 2020Review
- Endothelial Cell-Specific Molecule 1 Promotes Endothelial to Mesenchymal Transition in Renal Fibrosis.Toxins · 2020Article
- Increase of endocan, a new marker for inflammation and endothelial dysfunction, in acute kidney injury.Northern clinics of Istanbul · 2019Article
- Identification of ESM1 overexpressed in head and neck squamous cell carcinoma.Cancer cell international · 2019Article
- Is the plasma endocan level a reliable predictor for the severity of erectile dysfunction?International urology and nephrology · 2018Article
- Serum Endocan Levels Associated with Hypertension and Loss of Renal Function in Pediatric Patients after Two Years from Renal Transplant.International journal of nephrology · 2016Article
- Serum endocan levels in women with restless legs syndrome.Neuropsychiatric disease and treatment · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, endocan-formerly known as endothelial cell-specific molecule 1 (ESM-1)--was found to be associated with entities such as cancer, hypertension, renal transplant rejection, and chronic renal failure. Endothelial cells of many organs secrete endocan, but the exact functions of this relatively new molecule have not been elucidated completely. Emerging evidence suggests, however, that endocan plays an important role in inflammation, upregulation of cell adhesion molecules, lymphocyte functions, and endothelial cytoskeleton rearrangement. As suggested above, endocan has a prognostic impact in hypertension, transplant rejection, and chronic renal failure. In the current review, the evidence regarding endocan, hypertension, and chronic renal failure are summarized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.